About: Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $9.34 (+2.30%)
OCS NASDAQ Oculis Holding AG Ordinary shares
Oculis Holding AG Ordinary shares share price
OCS price activity
Último preço
$ 9,340
Variação (24h)
0,21 USD (2,30%)
Volume
434.68K
Volume (média 4 sem.)
-
Abertura
$ 9,20
Variação do dia
$ 9,02 - $ 9,48
Fechamento anterior
$ 9,13
Último negócio
30 Sep, 8:19 pm GMT+0
Atrasado
30 Sep, 8:19 pm GMT+0
OCS price performance
Atrasado
30 Sep, 8:19 pm GMT+0
quote.marketSignals